CSPC PHARMACEUTICAL GROUP LIMITED
石 藥 集 團 有 限 公 司
(Incorporated in Hong Kong with limited liability)
(Stock code: 1093)

VOLUNTARY ANNOUNCEMENT

**HIGHLY SELECTIVE FGFR4 INHIBITOR "SYHX2005"
OBTAINS CLINICAL TRIAL APPROVAL**

The board of directors (the "**Board**") of CSPC Pharmaceutical Group Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that the "SYHX2005" (the "**Product**") developed by the Group has obtained approval granted by the National Medical Products Administration of the People's Republic of China to conduct clinical trials in China.

The Product is a Class 1 innovative chemical drug developed by the Group with patent applications filed in China and overseas. The Product is a type of highly selective FGFR4 inhibitor and currently there are no products of the same type available in the global market. The indication for this clinical trial approval is for the treatment of advanced solid tumors. The preclinical studies have shown that the Product has a high selectivity of efficacy targets with excellent in vivo and in vitro activities as well as good safety profile, providing a promising clinical development value.

By order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 26 April 2022

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan and Mr. LAW Cheuk Kin Stephen as independent non-executive directors.